Suppr超能文献

临床评估 miR-34、miR-200、ZEB1 和 SNAIL EMT 调控枢纽,强调 EMTmiRs 驱动 EMT 及 NSCLC 术后患者预后的差异预后价值。

Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC.

机构信息

Assistance publique-hôpitaux de Paris, European Georges Pompidou Hospital, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Paris Cancer Institute CARPEM, Paris, France.

Centre de Recherche des Cordeliers, INSERM, CNRS SNC 5096, Sorbonne Université, Université de Paris, Paris, France.

出版信息

Br J Cancer. 2021 Nov;125(11):1544-1551. doi: 10.1038/s41416-021-01568-7. Epub 2021 Oct 12.

Abstract

BACKGROUND

Patients with non-small cell lung cancer (NSCLC) receiving curative surgery have a risk of relapse, and adjuvant treatments only translate into a 5% increase in 5-year survival. We assessed the clinical significance of epithelial-mesenchymal transition (EMT) and explored its association with the [SNAIL/miR-34]:[ZEB/miR-200] regulation hub to refine prognostic information.

METHODS

We validated a 7-gene EMT score using a consecutive series of 176 resected NSCLC. We quantified EMT transcription factors, microRNAs (miRs) of the miR-200, miR-34 families and miR-200 promoter hypermethylation to identify outcome predictors.

RESULTS

Most tumours presented with an EMT-hybrid state and the EMT score was not predictive of outcome. Individually, all miR-200 were inversely associated with the EMT score, but only chromosome-1 miRs, miR-200a, b, 429, were associated with disease-free survival (p = 0.08, 0.05 and 0.025) and overall survival (p = 0.013, 0.003 and 0.006). We validated these associations on The Cancer Genome Atlas data. Tumour unsupervised clustering based on miR expression identified two good prognostic groups, unrelated to the EMT score, suggesting that miR profiling may have an important clinical value.

CONCLUSION

miR-200 family members do not have similar predictive value. Core EMT-miR, regulators and not EMT itself, identify NSCLC patients with a low risk of relapse after surgery.

摘要

背景

接受根治性手术的非小细胞肺癌 (NSCLC) 患者有复发的风险,辅助治疗仅将 5 年生存率提高 5%。我们评估了上皮-间充质转化 (EMT) 的临床意义,并探讨了其与 [SNAIL/miR-34]:[ZEB/miR-200] 调节枢纽的关联,以完善预后信息。

方法

我们使用连续的 176 例 NSCLC 手术切除标本验证了一个 7 基因 EMT 评分。我们量化了 EMT 转录因子、miR-200 家族和 miR-200 启动子超甲基化的 microRNAs (miRs),以确定预后预测因子。

结果

大多数肿瘤呈 EMT-混合状态,EMT 评分不能预测预后。单独来看,所有 miR-200 都与 EMT 评分呈负相关,但只有染色体 1 的 miR-200a、b、429 与无病生存率 (p=0.08、0.05 和 0.025) 和总生存率 (p=0.013、0.003 和 0.006) 相关。我们在 The Cancer Genome Atlas 数据上验证了这些关联。基于 miR 表达的肿瘤无监督聚类鉴定了两个预后良好的组,与 EMT 评分无关,这表明 miR 谱分析可能具有重要的临床价值。

结论

miR-200 家族成员没有相似的预测价值。核心 EMT-miR、调节因子,而不是 EMT 本身,可识别手术后复发风险低的 NSCLC 患者。

相似文献

2
MicroRNA-105 promotes epithelial-mesenchymal transition of nonsmall lung cancer cells through upregulating Mcl-1.
J Cell Biochem. 2019 Apr;120(4):5880-5888. doi: 10.1002/jcb.27873. Epub 2018 Oct 14.
5
Decitabine reverses TGF-β1-induced epithelial-mesenchymal transition in non-small-cell lung cancer by regulating miR-200/ZEB axis.
Drug Des Devel Ther. 2017 Mar 28;11:969-983. doi: 10.2147/DDDT.S129305. eCollection 2017.
7
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Int J Oncol. 2016 Mar;48(3):937-44. doi: 10.3892/ijo.2016.3331. Epub 2016 Jan 11.
8
Competing Endogenous RNA of Snail and Zeb1 UTR in Therapeutic Resistance of Colorectal Cancer.
Int J Mol Sci. 2021 Sep 3;22(17):9589. doi: 10.3390/ijms22179589.

引用本文的文献

3
Non-coding RNA and drug resistance in head and neck cancer.
Cancer Drug Resist. 2024 Sep 20;7:34. doi: 10.20517/cdr.2024.59. eCollection 2024.
4
PrP controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up.
Oncogene. 2024 Sep;43(37):2781-2794. doi: 10.1038/s41388-024-03130-0. Epub 2024 Aug 15.
5
The role of miR-6884-5p in epithelial-mesenchymal transition in non-small cell lung cancer.
Aging (Albany NY). 2024 Jan 24;16(2):1968-1979. doi: 10.18632/aging.205474.
6
Recent advances on high-efficiency of microRNAs in different types of lung cancer: a comprehensive review.
Cancer Cell Int. 2023 Nov 20;23(1):284. doi: 10.1186/s12935-023-03133-z.
8
/MicroRNA-34 axis in cancer and beyond.
Heliyon. 2023 Apr 3;9(4):e15155. doi: 10.1016/j.heliyon.2023.e15155. eCollection 2023 Apr.
10
The Role of MicroRNA in the Regulation of Tumor Epithelial-Mesenchymal Transition.
Cells. 2022 Jun 21;11(13):1981. doi: 10.3390/cells11131981.

本文引用的文献

1
deficiency promotes lung cancer metastasis by activating Notch signaling in cancer-associated fibroblasts.
Genes Dev. 2021 Aug 1;35(15-16):1109-1122. doi: 10.1101/gad.347344.120. Epub 2021 Jul 22.
2
Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer.
N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19.
3
Guidelines and definitions for research on epithelial-mesenchymal transition.
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352. doi: 10.1038/s41580-020-0237-9. Epub 2020 Apr 16.
4
Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum.
Front Bioeng Biotechnol. 2020 Mar 20;8:220. doi: 10.3389/fbioe.2020.00220. eCollection 2020.
5
EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells.
Cell Death Dis. 2020 Feb 24;11(2):147. doi: 10.1038/s41419-020-2340-4.
7
MiR-34a and miR-34b/c have distinct effects on the suppression of lung adenocarcinomas.
Exp Mol Med. 2019 Jan 17;51(1):1-10. doi: 10.1038/s12276-018-0203-1.
9
EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):29-39. doi: 10.1016/j.bbcan.2018.10.003. Epub 2018 Nov 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验